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Abstract
Background: Antiepileptic drug (AED) induced dyskinesia is an unusual manifestation in the medical field. In the
previous case reports describing first generation-AED related involuntary movements, the authors suggested that a
plausible cause is pharmacokinetic interactions between two or more AEDs. To date, development of dyskinesia
after levetiracetam (LEV) has not been reported.
Case presentation: A 28-year-old woman with a history of brain metastasis from spinal cord glioblastoma
presented with several generalized tonic-clonic seizures without restored consciousness. LEV was administered
intravenously. Thereafter no more clinical or electroencephalographic seizures were noted on video-EEG
monitoring, while chorea movement was observed in her face and bilateral upper limbs.
Discussion and conclusions: To our knowledge, there is no case report of dyskinesia after administration of LEV.
Considering the temporal relationship and absence of ictal video-EEG findings, we suggest that development of
choreoathetosis was closely associated with the undesirable effects of LEV. We propose that dopaminergic system
dysregulation and genetic susceptibility might underlie this unusual phenomenon after LEV treatment.
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Background
Levetiracetam (LEV) is a second-generation antiepileptic
drug that is widely used for a variety of seizure types.
Intravenous LEV is also regarded as one of the treatment
options in status epilepticus. LEV generally has no ser-
iously harmful adverse effects except for psychiatric
problems and has quite limited pharmacokinetic interac-
tions with other antiepileptic drugs (AEDs). Dyskinesia
including choreathetosis, tremor, and dystonia often
develops after acute exposure to certain drugs such as
neuroleptics, antiemetics, or psychostimulants. There
have been previous reports about movement disorders
including tremor and parkinsonism after exposure to
AEDs (i.e., phenytoin, valproate, carbamazepine, gaba-
pentin, and phenytoin combined with lamotrigine) [1].
Case presentation
A 28-year-old woman visited the emergency room with
confused mental status after a few generalized tonic-
clonic seizure attacks. She had been treated for spinal
cord glioblastoma for 4 years. She had undergone surgical
removal of a spinal cord tumour and had been on con-
comitant chemoradiation therapy, which was terminated
2 weeks before the visit. CSF tap was not performed due
to an intracranial space occupying lesion.
Brain MRI performed 3months before the visit showed
extension of the tumour from the brainstem to the upper
thoracic spinal cord and another lesion at the right
temporal pole.
Figure 1 on presentation, she was drowsy and vital
signs were as follows: blood pressure, 125/65 mmHg;
body temperature, 36.4 °C; pulse rate, 100 per minute;
respiratory rate, 19/min. The emergency medical faculty
immediately gave her intravenous LEV 1000mg; how-
ever, there was one more generalised tonic-clonic seiz-
ure without mental recovery. Video-EEG monitoring
was initiated 2 h after the end of LEV loading; at that
time, she started to show choreoathetoid movements in
her face and bilateral limbs (see Additional file 1), but
no epileptiform discharges were noted on concomitant
electroencephalography (EEG) as seen in Fig. 2. Laboratory
findings including complete blood counts, electrolytes,
blood urea nitrogen, creatinine, and arterial ammonia levels
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were normal. Review of her medical history revealed that
she had been treated with solifenacin, esomeprazole, baclo-
fen, and escitalopram for more than 3months. She was not
on concomitant drugs such as dopamine receptor blockers
or antipsychotic agents. Considering the temporal relation-
ship between the onset of involuntary movements and
administration of LEV, further treatment with LEV
was withheld. Chorea movement continued for about
30 min. She could communicate with her caregiver
and physician until the end. After administration of 4mg
of lorazepam and 1200mg of phenytoin, the involuntary
movements ceased gradually. The next day her mental
status gradually improved and no more involuntary move-
ments were observed.
Discussion and conclusions
We judged that the initial seizures were closely related
to the patient’s brain lesion (right temporal lobe). Al-
though the drug was not tested by rechallenge, the grad-
ual improvement of chorea and no recurrence after
discontinuation of LEV suggests that the patient’s chorea
might be attributed to the effect of LEV. Also, under-
lying metabolic causes related to chorea could be ex-
cluded by laboratory findings.
Fig. 1 Brain MRI showed extension of glioblastoma of spinal cord to the brainstem and another lesion in the right temporal lobe
Fig. 2 EEG showed no epileptiform discharges during the episode of chorea movement
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For a seizure originating from mesial temporal lobe
and not propagating to lateral structures, the EEG could
be negative. However, she was able to communicate
while showing the movements, unlike mesial temporal
lobe seizures in which consciousness is usually impaired.
Moreover, a majority of automatism seizures lasts for
less than 1–2 min. Even though we suppose that she was
in a complex partial status epilepticus (CPSE), her on-
going movement did not accompany any epileptiform
discharges nor clinically evolving features for a relatively
long time during video-EEG monitoring, which does not
meet the commonly used diagnostic criteria for CPSE.
Use of benzodiazepines can alleviate or terminate not
only epileptic seizures but also involuntary movements
such as tremor, chorea, and dystonia. However, a possi-
bility remains that her symptom was a mesial temporal
lobe seizure with oromandibular and manual automa-
tisms because cessation of the movement was observed
after administration of other AEDs.
Most cases of anticonvulsant-induced chorea dyskinesia
have been reported in association with first-generation
AEDs [2]. A possible explanation includes pharmacoki-
netic interaction with other AEDs or concurrently admin-
istered medications, resulting in an additive or synergistic
effect on the central dopaminergic pathway [2]. In our
case, considering that the patient’s concomitantly adminis-
tered drugs were in stable use and not generally associated
with dopaminergic hyperactivity and furthermore, that
LEV has pharmacokinetic drug interactions with them, we
supposed that drug-to-drug interactions was not a pos-
sible mechanism.
Although the pharmacodynamic effect of LEV is not
fully elucidated, inhibition of synaptic vesicle proteins
including dopaminergic transmission is speculated to be
a probable mechanism for the development of dyskinesia.
According to previous reports, LEV showed a therapeutic
effect against tardive dyskinesia, which is known to be re-
lated to dopaminergic receptor hypersensitivity in long-
term neuroleptic users [3]. It was also experimentally
shown that LEV has a role in stabilizing levodopa-induced
dyskinesia in animals with MPTP-induced lesions [4].
These findings demonstrated that LEV could affect the
sensitivity of dopaminergic receptors. In our case, it can
be postulated that an acute decrease in synaptic activity
of D2 receptors after exposure to LEV was involved in
dopamine receptor dysregulation and led to paradoxical
hypersensitivity. The approximately 2-h delay between
introduction of LEV and development of chorea move-
ments supports this assumption.
Helmstaedter et al. [5] showed an association between
genetic variation causing decreased dopaminergic activ-
ity and psychiatric effects after LEV treatment, which in-
dicates the importance of appropriate and individualized
AED therapy based on a dopaminergic pathway genetic
profile. Genetic factors might explain the unexpected
phenomenon in our case. People carrying genetic vari-
ants associated with altered dopaminergic activity could
be at high risk for chorea after LEV treatment. To our
knowledge, this is the first report of dyskinesia after LEV
treatment. As LEV is widely used in the treatment of
epilepsy, clinical vigilance is required when patients
present with dyskinesia after initiation of LEV treatment.
Also, as can be seen from our case, video-EEG monitor-
ing is an important diagnostic method to not only ascer-
tain if an abnormal movement originated from a true
epileptic condition, but also to evaluate and make a dif-
ferential diagnosis among diverse movement phenomena
which can be confusing when treating epilepsy patients.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
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Additional file 1. Choreoathetoid movements of the patient’s face and
bilateral limbs.
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